CoChat

140-LB: NGM313, a Novel Activator of b-Klotho/FGFR1c, Improves Insulin Resistance and Reduces Hepatic Fat in Obese, Nondiabetic Subjects

DEPAOLI, ALEX, PHUNG, VAN, BASHIR, MUSTAFA R., MORROW, LINDA, BEYSEN, CARINE, YAN, ANDREW, LING, LEI, BAXTER, BRYAN, LUSKEY, KENNETH L., OLEFSKY, JERROLD M. · 2019 · Diabetes
Cited by 28

The DOI matches its Crossref record.

Abstract

Background: NGM313 is a humanized monoclonal antibody activator of β-klotho/FGFR1c that has been shown to reduce HOMA-IR in obese subjects. This study compared the effects of a single dose of NGM313 vs. daily pioglitazone (PIO) on insulin sensitivity, liver fat content (LFC) and lipids in insulin resistant, obese subjects with increased liver fat. Methods: 25 subjects were randomized 2:1 to either a single dose of NGM313 240 mg SC (n=17) or PIO 45 mg PO QD (n=8) for 36 days. Whole-body insulin sensitivity was determined by a two-step hyperinsulinemic, euglycemic clamp and LFC by magnetic resonance imaging-proton density fat fraction (MRI-PDFF). Results: (Table 1) A single dose of NGM313 significantly increased glucose disposal rate and was comparable to PIO. Suppression of endogenous glucose production was enhanced by both NGM313 and PIO. Significant reductions in LFC, HbA1c, serum triglycerides and LDL-C, and an increase in HDL-C, were observed with NGM313. NGM313 produced a greater reduction in LFC vs. PIO at day 23. The safety and tolerability profile was favorable for both drugs. Conclusion: NGM313 is a potent insulin sensitizer, comparable to PIO. In addition, NGM313 is highly effective in reducing LFC in subjects with increased liver fat. As such, NGM313 has significant potential to be an effective treatment for nonalcoholic steatohepatitis and type 2 diabetes. Disclosure: A. DePaoli: Employee; Self; NGM Biopharmaceuticals. V. Phung: Employee; Self; NGM Biopharmaceuticals. Stock/Shareholder; Self; NGM Biopharmaceuticals. M.R. Bashir: Consultant; Self; RadMD. Research Support; Self; Madrigal Pharmaceuticals, Metacrine Inc, NGM Biopharmaceuticals, Pinnacle Clinical Research, ProSciento, Siemens Corporation. L. Morrow: Employee; Spouse/Partner; Eli Lilly and Company. Employee; Self; ProSciento. C. Beysen: None. A. Yan: None. L. Ling: Employee; Self; NGM Biopharmaceuticals. Stock/Shareholder; Self; NGM Biopharmaceuticals. B. Baxter: Employee; Self; NGM Biopharmaceuticals. K.L. Luskey: Consultant; Self; NGM Biopharmaceuticals. J.M. Olefsky: None.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db19-140-lb

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

Metadata

Authors
DEPAOLI, A., PHUNG, V., BASHIR, M. R., MORROW, L., BEYSEN, C., YAN, A., LING, L., BAXTER, B., LUSKEY, K. L., & OLEFSKY, J. M.
Venue
Diabetes
Published
2019-06-01
Volume
68
Issue
Supplement_1
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2948900613
Cited by
28
References
0
FWCI
1.00
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.